Drugmaker Lykos Therapeutics introduced on Aug. 9, 2024, that the Meals and Drug Administration declined to approve the corporate’s utility for the usage of MDMA remedy within the therapy of post-traumatic stress dysfunction. It’s the first such determination issued on a psychedelic drug utility. US Meals and Drug Administration (FDA) rejects MDMA, also called ecstasy, as a psychiatric therapy.
source